Windtree Therapeutics, Inc. shares are trading higher Wednesday after the company completed enrollment of its SEISMiC Extension Phase 2b study of istaroxime in early cardiogenic shock caused by heart failure.

The Details: The company is hoping to build on the positive results from a previous study, the SEISMiC Phase 2 clinical study, regarding the ability of istaroxime to improve heart function and low blood pressure in the context of early cardiogenic shock due to heart failure.

Also, Windtree Therapeutics ( WINT ) hopes that the study confirms its observations from the prior study that the drug has a favorable renal profile and does not increase cardiac arrhythmias.

One key difference between this study and the SEISMiC Phase 2 clinical study is that the company is using a longer dosing duration and tapering the dosage to analyze potential benefits. Specifically, the study will extend the dosing duration from 24 hours to 60 hours. Additionally, one group of participants in the study will receive a constant dose of istaroxime, while another group will receive a decreasing dosage.

“We look forward to announcing topline results from the SEISMiC Extension Study by the end of the month and plan to present this data at a major medical meeting in the very near future,” said Steve Simonson, chief medical officer and senior vice president of Windtree.

See Also: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs

WINT Price Action: At the time of writing, Windtree stock is moving 18.6% higher at $3.78, according to data from Benzinga Pro.

Image: Emilian Danaila from Pixabay